Crawford Resigns as FDA Commissioner

Published Online: Saturday, October 1, 2005

After only 2 months as chief of the FDA, Lester Crawford, DVM, PhD, has resigned, stating that "it is time at the age of 67 to step aside." His resignation comes at a time marked by heavy disapproval of the agency and its decisions, including those related to drug safety and drug monitoring. The most recent bone of contention was Dr. Crawford's decision to delay Barr Laboratories' application to make emergency contraception available without a prescription, over the objections of staff scientists who said that the pill was safe.

The FDA also has come under fire for (1) its slow response to recognize the safety concerns of painkillers such as Merck's Vioxx, which was taken off the market in 2004 and is facing countless lawsuits from patients who claim that they were harmed by the drug; (2) the shutdown of a British supplier of the US flu vaccine for tainted shots; and (3) the regulation of heart defibrillators and other devices.

Andrew von Eschenbach, MD, has been named acting FDA commissioner. Before being confirmed as permanent FDA commissioner in July 2005, Dr. Crawford had served as acting or deputy FDA commissioner since February 2002.

Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues